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Abstract: Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or 
antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate 
cancer (mCRPC) postdocetaxel. Preclinical studies have demonstrated impressive affinity to the AR compared to the first-generation 
AR inhibitors. The landmark Phase III AFFIRM trial demonstrated improved overall survival benefit compared to placebo in addition to 
improvement in all tested parameters. Enzalutamide is currently being studied in several trials prechemotherapy and in earlier settings 
of prostate cancer. This review will discuss the mechanism of action of enzalutamide, its pharmacokinetics, the preclinical and clinical 
trials that led to its approval, the ongoing clinical trials, its safety and efficacy, as well as patterns of resistance, and discusses its place 
in therapy within the context of several recently approved agents for mCRPC.
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Introduction
Prostate cancer in the United States is expected to 
result in 239,000 cases in 2013 with a projected death 
of 29,700.1 Growth, as well as differentiation of the 
prostate gland, is largely dependent on androgens 
such as testosterone and dihydrotestosterone. Upon 
malignant transformation, prostate tumor growth 
is also driven by androgen signaling. In the 1940s, 
Huggins and Hodges2 first showed that the effects of 
surgical orchiectomy could lead to prostate cancer 
regression.2 Since that time, androgen suppression 
therapy (AST), through the use of gonadotropin-
releasing hormone (GnRH) agents (predominantly 
agonists and until recently, antagonists), has become 
the cornerstone of systemic treatment for metastatic 
prostate cancer. While AST results in prostate-specific 
antigen (PSA) responses in a majority of cases, 
relapse almost invariably ensues. Higher post-AST 
PSA levels predict recurrence, which signals expres-
sion of androgen-regulated genes.3 Relapse usually 
occurs within 12 to 24 months, as demonstrated by 
either rising PSA, radiologic worsening, or dete-
rioration of disease-related symptoms.4 Disease at 
this juncture has previously been considered to be 
“androgen-independent,” or “hormone-refractory,” 
or “hormone-resistant.” However, these terms are 
both a misnomer and misleading, since androgen 
receptor expression is almost never lost. Further evi-
dence and observation has shown that in many cases, 
the response to residual levels of androgens or other 
circulating hormones in a particular patient could 
be amplified due to one of several factors including 
mutation of the androgen receptor (AR) and altera-
tion in levels of cofactor proteins, and thus would 
still be sensitive to further hormonal manipulation.5 
Therefore, the term “castration-resistant” is now 
widely accepted and preferred.
In 2004, docetaxel was the first approved agent 
showing a survival advantage in men with metastatic 
castration-resistant prostate cancer (mCRPC) based on 
the two pivotal trials, SWOG 9916 and TAX-327, both 
of which demonstrated superior overall survival (OS) 
outcomes in men treated with docetaxel and predni-
sone compared with mitoxantrone and prednisone in 
the frontline setting,6,7 with updated results showing a 
sustained survival advantage.8 During this subsequent 
era, efforts have been made to search for varying 
targets as well as combinations with docetaxel, with 
the belief that once castration-resistance ensues, the 
AR ceases to be a target.9 In June 2010, a novel tax-
ane that was primarily studied in taxane-resistant 
models, cabazitaxel, was approved in the second-line 
setting based on the pivotal TROPIC trial.10 Several 
recent studies in mCRPC have made it apparent that 
prostate cancer growth remains dependent on andro-
gen supply after the disease becomes unresponsive to 
standard hormonal therapy.11 Based on these findings, 
renewed interest in using new therapeutic agents 
to target androgen-signaling for mCRPC patients 
was seen. Abiraterone acetate, an inhibitor of cyto-
chrome P450 17 (CYP17), in conjunction with pred-
nisone, received approval in April 2011 for mCRPC 
after docetaxel failure based on the COU-AA-301 
trial.12 Almost in parallel, enzalutamide (formerly 
MDV3100), an oral, second-generation AR inhibitor 
that competitively inhibits androgen binding to the 
AR and inhibits its nuclear translocation and inter-
action with deoxyribonucleic acid (DNA) was being 
developed. This review describes the pharmacologic 
parameters of this agent, its mechanism of action, 
and the clinical trials that led to its approval by the 
United States Food and Drug Administration (FDA), 
its safety and efficacy, and discusses its place in the 
proper sequencing treatment of prostate cancer.
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Mechanism of action
The AR is a 919-amino acid member of the steroid 
receptor transcription factor superfamily with different 
domains including an N-terminal regulation domain, 
a central DNA binding domain, and a C- terminal 
domain, which includes the ligand- binding domain 
incorporated within its protein  structure.13 Shortly 
after the initial discovery of the AR in the late 1960s, 
AR blockers have historically been included in the 
backbone of prostate cancer therapy. AR inhibitors 
serve as oral competitive inhibitors to endogenous 
ligands to the AR that when bound, induces a con-
formational change that ultimately result in the tran-
scription of AR-regulated genes. The initial steroidal 
antiandrogens had significant progestational effects, 
with compounds such as cyproterone acetate and 
megestrol acetate. Nonsteroidal antiandrogens were 
then developed and are more specific to the AR.14 
 Flutamide was discovered in the 1970s and was later 
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approved for use in treating prostate cancer in 1989. 
In 1995, bicalutamide was also approved and nilut-
amide followed a year later. In the 1980s, an approach 
of complete androgen blockade (CAB) or maximal 
androgen blockade, with a combination of antiandro-
gen antagonists and AST in an effort to eliminate or 
block all testicular and adrenal sources of androgen, 
was introduced.15 CAB garnered widespread support 
at one time, but because of potential added costs and 
toxicity in the setting of minimal added benefit,16 it 
was not uniformly adopted in practice. In addition, 
observations on the progression of use of peripheral 
androgen blockade, as well as a phenomenon of clini-
cal benefit upon discontinuation of antiandrogens has 
led to the antiandrogen withdrawal syndrome, which 
formed the basis to further understand androgen resis-
tance since antiandrogens function as partial agonists 
instead of antagonists.17 In addition, Sawyers et al18 
found that this resistance may partly be due to upreg-
ulation in AR expression.18
The new AR antagonist, enzalutamide, soon rep-
resented the latest addition in the arsenal of second-
ary hormonal manipulating agents. Enzalutamide 
was selected from a library of compounds for clinical 
development, not only because of its favorable drug-
like properties19 and its effect on castration-resistant 
prostate cancer (CRPC) xenograft models, but 
also due to its ability to inhibit AR signaling in 
the overexpression of AR cells with high binding 
affinity to the AR and lack of agonist activity.20,21 
Unlike  previous antiandrogens, enzalutamide tar-
gets multiple steps in the androgen-signaling path-
way (see Fig. 1).  Enzalutamide bound to the AR in 
a castration-resistant LNCaP/AR human prostate 
cancer cell model demonstrated an eightfold greater 
affinity than bicalutamide when evaluated using an 
18-fluoro-deoxyglucose-dihydrotestosterone scan to 
measure relative AR binding affinity in a competition 
assay.20 In addition to an increased binding affinity 
when bound to enzalutamide, the AR translocates 
into the nucleus far less efficiently, and a significant 
AR fraction remains in the cytosol. Enzalutamide 
induces regression of established LNCaP/AR xeno-
graft tumor cells, which overexpress ARs, growing 
in castrated male mice. Bicalutamide treatment, on 
the other hand, was shown to only retard growth. 
Enzalutamide antagonized induction of PSA and 
transmembrane serine protease 2, indicating a lack of 
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Figure 1. Mechanism of action of enzalutamide. enzalutamide has high 
affinity for the androgen receptor (AR) and does not promote transloca-
tion of the AR to the nucleus and its binding to DNA, thus leading to 
tumor death.
agonist activity. Regression seen with enzalutamide 
is associated with continued evidence of apoptosis up 
to 25 days after initiation of treatment.
Metabolism and pharmacokinetic profile
Based on the work done at Sawyers et al’s19 lab, 
a nonsteroidal thiohydantoin agonist was selected as 
the initial chemical framework due to its high affin-
ity and selectivity for the AR. After 200 derivatives 
were screened, the diarylthiohydantoin MDV3100 or 
enzalutamide, was selected for further preclinical and 
subsequently clinical studies.19 The pharmacokinet-
ics of enzalutamide (formula C21H16F4N4O2S) and its 
major metabolite, N-desmethyl enzalutamide, were 
evaluated in patients with mCRPC and healthy male 
volunteers. The plasma enzalutamide pharmacokinet-
ics, in the studied dose range between 30 mg to 480 mg 
given orally, exhibited a linear, two-compartmental 
model with first-order absorption.22 Following 
administration of one dose at 160 mg, enzalutamide 
was absorbed rapidly in patients with mCRPC, with 
median time to maximum plasma concentration of 
1 hour, ranging between 30 minutes and 3 hours. 
The terminal elimination half-life, in the same sub-
set of patients following a single dose, was noted to 
be 5.8 days with a range from 2.8 days to 10.2 days. 
Plasma concentrations reached a steady state by day 
28 of daily treatment and accumulated approximately 
8.3-fold relative to a single dose, with low daily 
fluctuations in plasma concentrations.
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In patients with mCRPC, the mean (%CV) pre-
dose Cmin or trough values for enzalutamide and 
N-desmethyl enzalutamide were 11.4 (25.9%) µg/mL 
and 13.0 (29.9%) µg/mL, respectively. The mean 
apparent total plasma clearance of enzalutamide 
was 0.56 L/hour (%CV: 29.9%).23 Enzalutamide was 
found to be mainly metabolized by cytochrome P450 
and more specifically, in vitro human CYP2C8 and 
CYP3A4. CYP2C8 is responsible for the formation 
of the active metabolite, N-desmethyl  enzalutamide. 
Following a single dose of 14C-enzalutamide 160 mg, 
plasma samples were analyzed for enzalutamide and 
its metabolites up to 77 days postdose. Enzalutamide, 
N-desmethyl enzalutamide, and a major inactive 
carboxylic acid metabolite accounted for 88% of the 
14C-radioactivity in plasma, representing 30%, 49%, 
and 10%, respectively, of the total 14C-AUC0-inf. 
Enzalutamide is excreted in the urine (71%) and 
feces (14%) mainly as inactive  metabolites. The 
plasma pharmacokinetics of enzalutamide and 
N-desmethyl enzalutamide were examined in vol-
unteers with normal renal and hepatic function, as 
well as those with mild (CrCl 60 to ,90 mL/minute) 
and moderate (CrCl 30 to ,60 mL/minute) renal 
impairment, as well as those with mild (Child Pugh 
Class A) and moderate hepatic impairment (Child 
Pugh Class B). The apparent clearance and compos-
ite area under the curve of enzalutamide was similar 
in patients with preexisting mild and moderate renal 
impairment, as well as in those with mild to moder-
ate baseline hepatic impairment, respectively, com-
pared to patients and volunteers with normal renal 
and hepatic function; hence, there are no recom-
mendations for initial dose adjustments or modifica-
tions for patients who have mild to moderate renal 
or hepatic impairment.
The metabolism of enzalutamide may be modi-
fied by the concomitant administration of drugs 
that are known inducers of CYP2C8 or CYP3A4. 
However, no formal drug interaction studies have 
evaluated the effect of specific inducers on enzalut-
amide pharmacokinetics. In vivo, the sum of enzalu-
tamide and N-desmethyl enzalutamide exposure was 
increased by 2.2-fold and 1.3-fold when it was coad-
ministered with gemfibrozil (strong CYP2C8 inhibi-
tor) or itraconazole (strong CYP3A4) inhibitor), 
respectively, suggesting the need for avoidance of 
such coadministration.23
clinical studies: preliminary  
studies/clinical studies
Given the important role of the AR in the patho-
genesis of prostate cancer, inhibition of the AR in 
addition to AST has been the subject of study in 
metastatic prostate cancer. However, the earlier AR 
inhibitors, bicalutamide and flutamide, demonstrated 
no significant improvement in OS in patients with 
hormone-sensitive metastatic prostate cancer.24–26 
Certainly, limitations of the first-generation AR 
inhibitors included their partial agonist activity in the 
presence of overexpression of the AR.18 In addition, 
compared to dihydrotestosterone, bicalutamide has a 
lower affinity for the AR.27 In early preclinical trials, 
enzalutamide showed a potency that was higher than 
earlier generations of antiandrogens including flut-
amide, nilutamide, and bicalutamide.20 Enzalutamide 
was found to have a ten-times greater affinity relative 
to bicalutamide, and contrary to the latter, was shown 
to be a pure antagonist to the AR. The encouraging 
preclinical results led to the initiation of a Phase I/II 
trial in humans.
Phase I/II study
In a Phase I/II trial assessing the efficacy and safety of 
enzalutamide, 140 patients with CRPC were enrolled 
at multiple centers to receive enzalutamide orally at 
doses ranging from 30 mg to 600 mg daily.22 The vast 
majority of the patients (78%) included in this trial 
had metastatic disease. Around 44% of the patients 
have not previously received treatment to the primary 
tumor, whereas 30% have previously undergone sur-
gery and 26% have previously received definitive 
radiation therapy. Around half of the patients have 
previously received chemotherapy and over 75% of 
the patients have previously received at least two 
lines of hormonal therapy. The maximum tolerated 
dose was determined to be 240 mg daily, and there 
was no additional benefit obtained from instituting 
higher dosages. Antitumor activity was observed at 
all tested dosages. The median time to radiological 
progression was 47 weeks for all patients and it was 
more prolonged in the chemotherapy-naïve group 
(.60 weeks) than in the chemotherapy pretreated 
group (29 weeks). Of the patients who had measur-
able disease, 22% had soft tissue response and of the 
patients who had bone disease, 56% had stabilized 
bone disease lasting 12 or more weeks. In addition, 
enzalutamide in prostate cancer
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49% of the patients had conversion from unfavorable 
(.5/7.5 mL) to favorable (,5/7.5 mL) circulating 
tumor cell counts, indicating a favorable effect on this 
adverse prognostic group of patients. The main side 
effects included headache, hot flashes, and fatigue. 
Fatigue was dose-dependent and occurred in 11% of 
the patients. Three patients developed seizures and 
those three patients were receiving the 360 mg dos-
age or higher, and two of the patients were on medi-
cations that lowered the seizure threshold. At longer 
follow-up and at the time of updated analysis, 18 of 
the enrolled patients remained in the study, with a 
median time on therapy of 131 weeks.28 The median 
time to PSA progression [as assessed by the Prostate 
Cancer Working Group 2 (PCWG2)]29 was 41 weeks 
and 20 weeks in the chemotherapy-naïve and the 
chemotherapy-pretreated groups,  respectively. The 
median radiographic PFS was 56 weeks and 24 weeks 
in the chemotherapy-naïve and the chemotherapy-
pretreated group, respectively.
Phase III study: The AFFIRM study
Following the encouraging results of the Phase I/II 
trial, the Phase III AFFIRM trial (A Study Evaluating 
the Efficacy and Safety of the Investigational Drug 
MDV3100) was designed. The AFFIRM trial was an 
international double-blind placebo controlled trial in 
men with mCRPC who have failed prior docetaxel-con-
taining chemotherapy regimens.30 A total of 1,199 men 
with mCRPC from 166 sites were randomized in a 
2:1 manner to receive either enzalutamide 160 mg 
daily (n = 800) or placebo (n = 399). Glucocorticoids 
were not required, but were allowed and were seen in 
about 30% of patients in both arms. The primary end-
point of the trial was OS. Secondary endpoints included 
radiographic PFS, time to PSA progression, quality of 
life, and time to the first skeletal-related event (SRE). 
Patients were eligible to be enrolled in the trial if they 
had progressed on prior chemotherapy which con-
tained docetaxel, they had adequated organ function, 
an Eastern Cooperative Oncology group (ECOG) per-
formance status of 0–2. Around 50% of the patients in 
both arms had received at least three prior lines of hor-
monal therapy, and 24% of the patients had received 
two prior lines of therapy. An interim analysis was 
planned after a total of 520 deaths had occurred.
In view of the improved OS favoring enzalutamide, 
the study was unblinded at the recommendation of 
the Data and Safety Monitoring Committee, and the 
patients on placebo were allowed to cross-over to 
receive enzalutamide. Despite this cross-over, after a 
median follow-up of 14 months, the median OS was 
significantly improved in the enzalutamide arm ver-
sus the placebo arm [18.4 months versus 13.6 months, 
respectively; hazard ratio (HR), 0.63; 95% confidence 
interval (CI), 0.53–0.75; P , 0.0001]. This 4.8-month 
difference in OS translated in a 37% reduction in the risk 
of death of any cause in the enzalutamide arm. A sub-
group analysis showed that enzalutamide was supe-
rior to placebo, even in poor-risk categories including 
those with lower hemoglobin, higher alkaline phos-
phatase, worse Eastern Cooperative Oncology Group 
(ECOG) status, the presence of visceral disease, and 
the presence of pain. The group of patients who did 
not appear to benefit from enzalutamide was the one 
that included patients who received two or more prior 
chemotherapy regimens. Enzalutamide was superior 
to placebo in all the examined secondary endpoints. 
Enzalutamide was associated with improved time to 
PSA progression by 5.3 months (8.3 months versus 
3 months; HR, 0.25; P , 0.001) and improved median 
radiographic PFS by 5.4 months (8.3 months versus 
2.9 months; HR, 0.40; P , 0.001). Enzalutamide 
also demonstrated a superior PSA response with at 
least a 50% PSA reduction in 54% of the treated 
patients compared with 1.5% in the placebo arm 
(P , 0.001) and at least a 90% PSA reduction in 25% 
of the treated patients compared to 1% in the placebo 
arm (P , 0.001). Among patients who had measur-
able disease, Response Evaluation Criteria In Solid 
Tumors overall response rates (ORRs) were 29% in 
the enzalutamide arm compared to 4% in the placebo 
arm (P , 0.0001). Enzalutamide also resulted in an 
improvement in the time to first SRE (16.7 months ver-
sus 13.3 months; HR, 0.62; P , 0.0001) and quality 
of life response rate as determined by the Functional 
Assessment of Cancer Therapy-Prostate (FACT-P) 
(43% versus 18%; P , 0.0001). There were also 
beneficial effects on health-related quality of life, as 
reported in an updated analysis.31 Pain palliation was 
defined as .30% decline in the median pain score 
after 12 weeks of treatment compared to pretreatment 
pain score without a .30% increase in the use of 
analgesics. Pain palliation was achieved in 45% and 
7% of the patients in the enzalutamide and placebo 
arms respectively (P = 0.008), and pain progression 
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occurred in 28% of the patient on enzalutamide com-
pared to 39% in the patients on placebo (P = 0.002). 
Median time to pain progression on the FACT-P scale 
was not reached for the enzalutamide arm compared 
to 13.8 months for the placebo arm, thus represent-
ing a 44% risk reduction (HR, 0.56; P = 0.0004). 
Interestingly a post hoc analysis showed that patients 
who were taking corticosteroids at baseline in both 
arms had inferior survival compared to those who 
were not on steroids.32 In addition, on-study corticos-
teroid use was also associated with inferior OS and a 
significantly worse side-effect profile compared to the 
placebo group (grade 3–4 adverse events of 63.3% in 
the corticosteroid cohort versus 34.4% in the noncor-
ticosteroid cohort).33 One explanation could be that 
the patients who had introduced steroids to their ther-
apy might have had more severe disease at baseline. 
This is evident also in the recent American Society of 
Clinical Oncology (ASCO) presentation on the effect 
of baseline corticosteroid use in men undergoing the 
COU-AA-301 trial, which showed that while there is 
a decline in the OS and a worse time to progression 
on baseline corticosteroid use, this may be a mere 
reflection of a preexisting, overall poorer prognos-
tic risk of patients.34 Subsequent anticancer therapy 
was common in both arms (41% of the enzalutamide 
patients and 58% of the patients on placebo). The 
most common posttrial therapies included abirater-
one (21% and 24% in the enzalutamide and placebo 
arms, respectively), cabazitaxel (10% and 14% in the 
enzalutamide and placebo arms, respectively), doc-
etaxel (9% and 14% in the enzalutamide and placebo 
arms, respectively), and mitoxantrone (3% and 11% 
in the enzalutamide and placebo arms, respectively). 
On August 31, 2012, based on the overwhelming pos-
itive findings seen from the AFFIRM trial, the FDA 
approved enzalutamide given at 160 mg daily for men 
with mCRPC who had already received a docetaxel-
containing chemotherapy regimen.
Recent and ongoing trials
A Phase II trial evaluated the role of enzalutamide 
as monotherapy in hormone-naïve prostate can-
cer, and the results of the trial were reported at the 
ASCO 2013 annual meeting.35,36 The trial included 
67 patients, 39% of whom had metastatic dis-
ease, 36% had prior prostatectomy, and 24% had 
radiation therapy. Enzalutamide achieved a high 
median PSA response of 93% with a marked PSA 
decline of −99.6%. In contrast to castration, there 
was no change in the measured bone density or in 
the measured metabolic variables such as body fat 
mass, or glycemic and lipid profiles. The prelimi-
nary results of the Phase I study that evaluated the 
combination of enzalutamide with docetaxel in the 
chemotherapy-naïve mCRPC setting were also pre-
sented at the ASCO 2013 meeting.37 In that Phase I 
trial, enzalutamide did not appear to alter tolerability 
to docetaxel or affect its pharmacokinetics.37
A number of trials are currently underway to 
evaluate the role of enzalutamide in a wide range of 
patient populations and clinical settings. The safety of 
the combination of the new novel agents, abiraterone 
and enzalutamide, in mCRPC to the bones is being 
studied in a Phase II trial (NCT01650194). In addi-
tion, a Phase III trial comparing abiraterone acetate to 
abiraterone acetate with prednisone and enzalutamide 
(Alliance A03121, funded through the Biomarker, 
Imaging, and Quality of Life Studies Funding Pro-
gram of the National Cancer Institute) seeks to enroll 
1428 mCRPC chemotherapy-naïve patients with an 
endpoint of OS. Two Phase II randomized trials are 
comparing the combination of the PSA-TRICOM vac-
cine with enzalutamide to enzalutamide alone both in 
the hormone-sensitive chemotherapy-naïve metastatic 
setting and the nonmetastatic setting (NCT01867333 
and NCT01875250). To ascertain whether enzalu-
tamide would have a place in the prechemotherapy 
setting, a Phase III randomized study of enzalut-
amide versus placebo in men with chemotherapy-
 naïve mCRPC (PREVAIL study; NCT01212991) was 
designed and has completed accrual with the results 
eagerly awaited. Enzalutamide is being compared 
to bicalutamide in the prechemotherapy setting in 
two Phase II trials, both in the nonmetastatic and the 
metastatic setting (NCT01288911, NCT01664923). 
A selected list of these trials is shown in Table 1.
safety
Enzalutamide seems to be very well tolerated with a 
favorable side effect profile. In the Phase I/II study,22 
the most common grade 3–4 adverse event was dose-
dependent fatigue (11% of patients), which was only 
observed at doses of 240 mg or greater, and generally 
resolved after dose reduction. In this trial, the three 
patients who developed seizures were receiving the 
enzalutamide in prostate cancer
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360 mg dose or higher, and two of the patients were 
on medications that lowered the seizure threshold. 
In the AFFIRM study,30 there were few toxicities 
that were more common in the enzalutamide arm, 
and these included fatigue (all grades, 34% versus 
29.1%), diarrhea, musculoskeletal pain, headache, 
hypertension, and hot flashes. Overall, the enzalu-
tamide group had a lower incidence of grade 3–4 
adverse events (45.3% versus 53.1%). Enzalutamide 
was also fairly well tolerated, with the most common 
adverse reactions (occurring in .5% of patients) 
including asthenia (34%), back pain, diarrhea (21%), 
arthralgia, hot flashes (20%), peripheral edema, respi-
ratory infection, muscular weakness, musculoskeletal 
pain, headache (12%), dizziness, insomnia, upper or 
lower respiratory infection, anxiety, hypertension, 
spinal cord compression, cauda equina syndrome, 
paresthesias, and hematuria, although a number of 
these latter adverse events were perhaps secondary to 
prostate cancer itself rather than medication-induced 
side effects. Their incidence was equally present in 
both the treatment and the placebo arms. Seizure 
was reported in five patients in the enzalutamide arm 
(versus none in the placebo arm) during the Phase III 
trial with two further seizure events reported in the 
follow-up data.23 However, certain risk factors for 
lowering the threshold for seizure may have been 
identified in these studies. Of the five patients who 
experienced seizures, two had brain metastases, one 
received lidocaine, and one patient had brain atro-
phy due to alcohol. There have been no reported sei-
zures following discontinuation of enzalutamide. The 
occurrence of seizure is postulated to be related to 
the inhibition of γ-aminobutyric acid (GABA)-gated 
chloride channels by enzalutamide. In the AFFIRM 
study, patients with history of seizures or those who 
were on medications that lowered the seizure thresh-
old were excluded from the Phase III trial. Including 
the two patients that experienced seizures in the lon-
ger follow-up of the AFFIRM study, the overall com-
bined seizure risk was 1% (ten out of 940 patients). 
As outlined in the pharmacokinetics section, several 
drugs that are strong CYP2C8 inhibitors should be 
avoided since increased plasma exposure to enzalu-
tamide can be seen, as well as avoidance of strong 
or moderate CYP3A4 or CYP2C8 inducers and sub-
strates to CYP3A4, CYP2C9, and CYP2C19 with 
narrow therapeutic indices.23
Efficacy
The efficacy of enzalutamide has been widely demon-
strated by the AFFIRM trial.30 Although the Phase I/II 
study showed that toxicity was significantly increased 
at doses higher than 240 mg, there was no additional 
benefit observed beyond the dose of 160 mg daily. 
Therefore, the 160 mg daily dose was selected as the 
optimal dosing regimen in the Phase III AFFIRM 
study that formed the basis of FDA approval. The 
Phase I/II study demonstrated that enzalutamide was 
effective both in the chemotherapy-naïve and the 
chemotherapy pretreated group. The AFFIRM study 
included only patients postdocetaxel, and demon-
strated that all endpoints including OS, radiographic 
PFS, time to PSA progression, quality of life, pain 
palliation, and time to the first SRE were improved 
with enzalutamide. The anticipated results of the 
PREVAIL study will ascertain whether enzalutamide 
will play a role in the prechemotherapy setting and 
will likely further change the therapeutic landscape 
in prostate cancer.
patient preference
Since the approval of docetaxel in 2004, there are 
now five agents that have shown to improve sur-
vival in mCRPC and these include sipuleucel-T,38 
cabazitaxel,10 abiraterone,39 and radium 223,40 in 
addition to enzalutamide. Enzalutamide is the sec-
ond oral hormonal agent (after abiraterone) that can 
extend survival in patients with mCRPC who were 
previously treated with docetaxel. No direct compari-
son with abiraterone acetate is available. One advan-
tage of enzalutamide over abiraterone is that it does 
not require the coadministration of corticosteroids, 
and thus be a better treatment option in the patient 
population with comorbidities where corticosteroids 
have the potential for significant side effects. On the 
other hand, enzalutamide might not be suitable for 
patients with a history of seizures or who are concur-
rently receiving medications that lower the seizure 
threshold—a side effect not seen with abiraterone 
use. However, there is currently no specific guidelines 
or biomarkers that would predict the best sequence,41 
timing, and specific population of patients that would 
benefit from each of those agents. Several groups 
have advocated for specific guidance on the use of 
varying approved therapies that look mainly at symp-
toms, such as the American Urologic Association42 
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and the National Cancer Comprehensive Network 
(NCCN),43 though with the understanding that given 
the rapidly evolving changes in the field, tailoring 
treatment as the therapeutic landscape changes will 
become appropriate as the literature changes.
place in Therapy
The positive effects seen in the AFFIRM trial led 
to the approval by the US FDA of enzalutamide in 
the postchemotherapy setting. Currently, this is the 
setting that has garnered widespread acceptance 
in therap. However, results of the PREVAIL study 
(which entailed enzalutamide given prior to chemo-
therapy) are eagerly awaited and may soon join the 
ranks of abiraterone given prechemotherapy. The 
exact role of the sequencing of these agents, or per-
haps their use in combination, remains uncertain. The 
aforementioned Alliance A03121 trial may further 
inform the utility of the combination of abiraterone 
acetate with enzalutamide versus abiraterone mono-
therapy in the prechemotherapypre-chemotherapy 
mCRPC setting. Given the currently available lit-
erature, per the NCCN for instance, enzalutamide 
has a category 1 recommendation postdocetaxel che-
motherapy, but has a category 2A recommendation, 
which equates to a consensus based on lower-level 
evidence for docetaxel-naïve men.44 Furthermore, 
varying studies are now looking at the utility of com-
bining enzalutamide with a vaccine, or combination 
with abiraterone, or using it in an earlier setting, as 
has been shown in the enzalutamide monotherapy for 
hormone-naïve prostate cancer.35,36
Concerns remain regarding the emergence of resis-
tance, especially since resistance invariably occurs 
with these agents. There are emerging retrospec-
tive data on the modest clinical activity observed, as 
well as on the brief duration of responses with the 
use of abiraterone after failure of prior docetaxel and 
enzalutamide therapy.45,46 Given initial approval and 
widespread use of abiraterone in 2011, and before 
approval of enzalutamide in 2012, most patients who 
would have received abiraterone and subsequently 
switched to enzalutamide may not experience the 
same benefit as was seen in the AFFIRM trial.41 
Further analysis of the AFFIRM trial also shows that 
in the subgroup analyses, men who had two or more 
prior chemotherapy treatments did not do as well (with 
HRs based on the nonstratified proportional hazards 
model approaching 1), leading perhaps to consider-
ation for earlier hierarchy in the sequencing.47 There 
have been varying hypotheses on the mechanisms of 
resistance,48 but cross-resistance conceivably be seen 
with these agents as well. One such mechanism sug-
gests that treatment with enzalutamide or abiraterone 
leads to an adaptive shift towards an AR-splice-
variant signaling, which gives rise to an increase in 
the constitutively active AR-splice variants that lack 
the AR-binding domain in prostate cancer.49 This is 
further elucidated by restoration of responsiveness 
to antiandrogens by knock-down experiments of 
AR-V expression.50 Another potential mechanism 
postulates an association with cellular Fas-associated 
death domain-like interleukin 1β-converting enzyme 
inhibitory protein expression, which plays a key role 
in mediating therapeutic resistance and maintaining 
viability of prostate cancer cells.51 A recent study that 
highlights the development of cell lines that were 
resistant to both enzalutamide and ARN-509, another 
novel antiandrogen, showed that the presence of a 
missense mutation (F876L) in the ligand-binding 
domain of the AR conferred resistance to both com-
pounds52 by converting to an AR agonist. Interestingly, 
a molecular dynamics simulation performed led to a 
chemical screen, which further identified additional 
novel compounds that effectively antagonized AR 
F876L to suppress the growth of prostate cancer cells 
resistant to enzalutamide.53
Ultimately, the sequencing of these agents is of 
paramount importance, as it enables patients to see 
through all possible treatments that afford clinical 
benefit and bring about survival. Currently, how-
ever, no biomarker exists that would reliably predict 
responses to one agent over another, although enzalu-
tamide would conceivably be effective even in the 
setting of low levels of circulating androgens, while 
higher levels of baseline-circulating androgens such as 
testosterone and dehydroepiandrostenedione, as well 
as ETS(erythroblast transformation specific)-related 
gene rearrangements, may predict the likelihood of 
response with abiraterone.54,55
conclusion
The design, development, and approval of enzalut-
amide lend insights into one of the most anticipated suc-
cesses in prostate cancer therapy. While the approval 
of enzalutamide currently resides in the postdocetaxel 
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space, there are promising reports of this drug being 
used in an earlier setting and may soon change the 
landscape of treatment for prostate cancer; however, 
resistance to enzalutamide also inevitably occurs. 
Thus, by improving the level of understanding of the 
mechanisms of resistance, the potential for combina-
tion with other agents, and the use of this agent across 
various settings of disease states in prostate cancer 
have garnered wide research efforts in this field, and 
will pave the way for better optimization of enzalut-
amide use in the treatment of prostate cancer.
Author contributions
Wrote portions of the first draft of the manuscript: JE, 
NP, AF, JBA. Contributed to the writing of the manu-
script: JE, NP, AF, JBA. Agree with manuscript results 
and conclusions: JE, NP, AF, JBA. Jointly developed 
the structure and arguments for the paper: JE, NP, 
AF, JBA. Made critical revisions and approved final 
version: JE, NP, AF, JBA. All authors reviewed and 
approved of the final manuscript.
Funding
Authors disclose no funding sources.
competing Interests
All other authors (other than J Aragon-Ching as stated 
below) have no conflict of interest. Dr. Aragon-Ching 
has served on the Advisory Board for Amgen and 
Janssen/Ortho-Biotech, and has served on the Speakers 
Bureau for Janssen/Ortho-Biotech, Sanofi-Aventis, 
and Astellas/Medivation.
Disclosures and ethics
As a requirement of publication the authors have pro-
vided signed confirmation of their compliance with 
ethical and legal obligations including but not lim-
ited to compliance with ICMJE authorship and com-
peting interests guidelines, that the article is neither 
under consideration for publication nor published 
elsewhere, of their compliance with legal and ethi-
cal guidelines concerning human and animal research 
participants (if applicable), and that permission has 
been obtained for reproduction of any copyrighted 
material. This article was subject to blind, indepen-
dent, expert peer review. The reviewers reported no 
competing interests. Provenance: the authors were 
invited to submit this paper.
References
 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J 
Clin. 2013;63(1):11–30.
 2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of 
castration, of estrogen and androgen injection on serum phosphatases 
in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4): 
232–40.
 3. Ryan CJ, Smith A, Lal P, et al. Persistent prostate-specific antigen expression 
after neoadjuvant androgen depletion: an early predictor of relapse or 
incomplete androgen suppression. Urology. 2006;68(4):834–9.
 4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate 
cancer. JAMA. 2005;294(2):238–44.
 5. Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate 
cancer: what lies on the horizon? BJU Int. 2008;101(3):271–4.
 6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramus-
tine compared with mitoxantrone and prednisone for advanced refractory 
prostate cancer. N Engl J Med. 2004;351(15):1513–20.
 7. Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel 
plus prednisone or mitoxantrone plus prednisone for advanced prostate 
cancer. N Engl J Med. 2004;351(15):1502–12.
 8. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. 
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced 
prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 
2008;26(2):242–5.
 9. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-
directed strategies for the treatment of prostate cancer: a new era of hor-
monal therapies is born. Ther Adv Urol. 2012;4(4):167–78.
 10. de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone 
plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate 
cancer progressing after docetaxel treatment: a randomised open-label trial. 
Lancet. 2010;376(9747):1147–54.
 11. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic 
steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treat-
ing metastatic prostate cancer. BJU Int. 2005;96(9):1241–6.
 12. de Bono JS, Logothetis CJ, Molina A, et al; COU-AA-301 Investigators. 
Abiraterone and increased survival in metastatic prostate cancer. N Engl J 
Med. 2011;364(21):1995–2005.
 13. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 
2002;20(13):3001–15.
 14. Sharifi N. Hormonal therapy for prostate cancer: toward further unraveling 
of androgen receptor function. Anticancer Agents Med Chem. 2009;9(10): 
1046–51.
 15. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of 
prostate cancer: complete instead of partial withdrawal of androgens. 
Prostate. 1983;4(6):579–94.
 16. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-
analysis of monotherapy compared with combined androgen blockade 
for patients with advanced prostate carcinoma. Cancer. 2002;95(2): 
361–76.
 17. Scher HI, Kolvenbag GJ. The antiandrogen withdrawal syndrome in 
relapsed prostate cancer. Eur Urol. 1997;31 Suppl 2:3–7; discussion 24–7.
 18. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance 
to antiandrogen therapy. Nat Med. 2004;10(1):33–9.
 19. Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydan-
toin androgen receptor antagonists for castration-resistant prostate cancer 
(CRPC). J Med Chem. 2010;53(7):2779–96.
 20. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antian-
drogen for treatment of advanced prostate cancer. Science. 2009;324(5928): 
787–90.
 21. Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S. Enzalutamide, 
an androgen receptor signaling inhibitor, induces tumor regression in a 
mouse model of castration-resistant prostate cancer. Prostate. 2013;73(12): 
1291–305.
 22. Scher HI, Beer TM, Higano CS, et al; Prostate Cancer Foundation/
Department of Defense Prostate Cancer Clinical Trials Consortium. 
Antitumour activity of MDV3100 in castration-resistant prostate cancer: 
a phase 1–2 study. Lancet. 2010;375(9724):1437–46.
enzalutamide in prostate cancer
Clinical Medicine Insights: Oncology 2013:7 245
 23. Xtandi [Package Insert]. Northbrook, IL: Astellas Pharma US, Inc. 
Available from: http://www.astellas.us/docs/12A005-ENZ-WPI.PDF. Accessed 
Jun 29, 2013.
 24. Fosså SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients 
with prostate cancer symptomatically progressing after androgen-ablative 
therapy: a phase III study of the European organization for research and 
treatment of cancer genitourinary group. J Clin Oncol. 2001;19(1):62–71.
 25. Akaza H, Hinotsu S, Usami M, et al. Study Group for the Combined Andro-
gen Blockade Therapy of Prostate Cancer. Combined androgen blockade 
with bicalutamide for advanced prostate cancer: long-term follow-up of a 
phase 3, double-blind, randomized study for survival. Cancer. 2009;115(15): 
3437–45.
 26. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of 
leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 
1989;321(7):419–24.
 27. Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of 
non-steroidal antiandrogens: translation of preclinical findings into clinical 
activity. Prostate Cancer Prostatic Dis. 1998;1(6):307–14.
 28. Higano CS, Beer TM, Taplin M, et al. Antitumor activity of MDV3100 in 
pre- and post-docetaxel advanced prostate cancer: long-term follow-up of a 
phase I/II study. J Clin Oncol. 2011;29(Suppl 7):Abstr 134.
 29. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working 
Group. Design and end points of clinical trials for patients with progressive 
prostate cancer and castrate levels of testosterone: recommendations of the 
Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7): 
1148–59.
 30. Scher HI, Fizazi K, Saad F, et al; AFFIRM Investigators. Increased survival 
with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 
2012;367(13):1187–97.
 31. Miller K, Scher HI, Fizazi K, et al. Effect of enzalutamide on health-related 
quality of life (HRQoL) in men with metastatic castration-resistant pros-
tate cancer (mCRPC) following docetaxel-based therapy: results from the 
AFFIRM study. ASCO Meeting Abstracts. 2013;31(Suppl 6):Abstr 17.
 32. Scher H, Fizazi K, Saad F, et al. Association of baseline corticosteroid 
with outcomes in a multivariate analysis of the Phase 3 AFFIRM study of 
Enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). 
Ann Oncol. 2012;23(Suppl 9):Abstr 899PD.
 33. Scher HI, Fizazi K, Saad F, et al. Impact of on-study corticosteroid use on 
efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), 
an androgen receptor inhibitor. J Clin Oncol. 2013;31(Suppl 6):Abstr 6.
 34. Montgomery RB, Kheoh TS, Molina A, et al. Effect of corticosteroid (CS) 
use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abi-
raterone acetate (AA): Results from a randomized study (COU-AA-301) in 
metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). 
J Clin Oncol. 2013;31(Suppl):Abstr 5014.
 35. Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherapy: 
Phase II study results in patients with hormone-naive prostate cancer. 
J Clin Oncol. 2013;31(Suppl 6):Abstr 18.
 36. Smith MR, Borre M, Rathenborg P, et al. Efficacy and safety of enzalu-
tamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). 
J Clin Oncol. 2013;31(Suppl):Abstr 5001.
 37. Fleming MT, Rathkopf DE, Gibbons J, et al. Enzalutamide in combination 
with docetaxel in men with prostate cancer (PC): preliminary results from a 
phase I study. J Clin Oncol. 2013;31(Suppl 6):Abstr 63.
 38. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. 
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. 
N Engl J Med. 2010;363(5):411–22.
 39. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with 
docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): 
a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.
 40. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, 
double-blind, randomized, multinational study of radium-223 chloride in 
castration-resistant prostate cancer (CRPC) patients with bone metastases 
(ALSYMPCA). J Clin Oncol. 2012;30(Suppl 18):LBA4512.
 41. Aragon-Ching JB. Is there an optimal treatment sequencing strategy for 
metastatic castration-resistant prostate cancer? Future Oncol. 2013;9(5): 
619–22.
 42. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: 
AUA guideline. J Urol. 2013;190(2):429–38.
 43. Choudhury AD, Kantoff PW. New agents in metastatic prostate cancer. 
J Natl Compr Canc Netw. 2012;10(11):1403–9.
 44. Kantoff PW, Mohler JL. New developments in the management of prostate 
cancer. J Natl Compr Canc Netw. 2013;11(Suppl 5):653–7.
 45. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical 
activity of abiraterone acetate in patients with metastatic castration-resistant 
prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7): 
1802–7.
 46. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone 
acetate against metastatic castration-resistant prostate cancer progressing 
after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7): 
1807–12.
 47. Aragon-Ching JB. Enzalutamide (formerly MDV3100) as a new  therapeutic 
option for men with metastatic castration-resistant prostate cancer. 
Asian J Androl. 2012;14(6):805–6.
 48. Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in 
castration-resistant prostate cancer and mechanisms of resistance to new 
agents targeting the androgen axis. Oncogene. Epub Jun 10, 2013.
 49. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated 
by the ligand-dependent full-length androgen receptor and its splice variants 
in castration-resistant prostate cancer. Cancer Res. 2012;72(14):3457–62.
 50. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. 
Androgen receptor splice variants mediate enzalutamide resistance in 
castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2):483–9.
 51. McCourt C, Maxwell P, Mazzucchelli R, et al. Elevation of c-FLIP in castrate-
resistant prostate cancer antagonizes therapeutic response to androgen 
receptor-targeted therapy. Clin Cancer Res. 2012;18(14):3822–33.
 52. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor muta-
tion confers resistance to 2nd generation anti-androgens enzalutamide and 
ARN-509. Cancer Discov. Epub Jun 18, 2013.
 53. Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based 
resistance to antiandrogens with rational drug design. Elife. 2013;2: 
e00499.
 54. Ryan CJ, Li J, Kheoh T, Scher HI, Molina A. Baseline serum adre-
nal androgens are prognostic and predictive of overall survival (OS) in 
patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): 
Results of the COU-AA-301 phase 3 randomized trial. Cancer Res. 
2012;72(8):AM2012-LB-434.
 55. Attard G, De Bono JS, Li W, et al. ERG rearrangements and association 
with clinical outcome in patients (pts) receiving abiraterone acetate (AA): 
results from the COU-AA-302 study in chemotherapy (chemo)-naïve 
metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 
2013;31(Suppl):Abstr 5004.
